SEARCH

SEARCH BY CITATION

References

  • Akbasak A., Toevs C. C. and Laske D. W. (1996) Reconstituted basement membrane (matrigel) enhances the growth of human glioma cell lines in nude mice. J. Neurooncol. 27, 2330.
  • Bernard-Pierrot I., Delbe J., Caruelle D., Barritault D., Courty J. and Milhiet P. E. (2001) The lysine-rich C-terminal tail of heparin affin regulatory peptide is required for mitogenic and tumor formation activities. J. Biol. Chem. 276, 12 22812 234.
  • Bridge A. J., Pebernard S., Ducraux A., Nicoulaz A. L. and Iggo R. (2003) Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 34, 263264.
  • Canoll P. D., Barnea G., Levy J. B., Sap J., Ehrlich M., Silvennoinen O., Schlessinger J. and Musacchio J. M. (1993) The expression of a novel receptor-type tyrosine phosphatase suggests a role in morphogenesis and plasticity of the nervous system. Brain Res. Dev. Brain Res. 75, 293298.
  • Chauhan A. K., Li Y. S. and Deuel T. F. (1993) Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice. Proc. Natl Acad. Sci. USA 90, 679682.
  • Fang W., Hartmann N., Chow D. T., Riegel A. T. and Wellstein A. (1992) Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J. Biol. Chem. 267, 25 88925 897.
  • Grzelinski M., Bader N., Czubayko F. and Aigner A. (2005) Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma. Int. J. Cancer 117, 942951.
  • Harroch S., Palmeri M., Rosenbluth J., Custer A., Okigaki M., Shrager P., Blum M., Buxbaum J. D. and Schlessinger J. (2000) No obvious abnormality in mice deficient in receptor protein tyrosine phosphatase beta. Mol. Cell. Biol. 20, 77067715.
  • Harroch S., Furtado G. C., Brueck W., Rosenbluth J., Lafaille J., Chao M., Buxbaum J. D. and Schlessinger J. (2002) A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions. Nat. Genet. 32, 411414.
  • Herold-Mende C., Mueller M. M., Bonsanto M. M., Schmitt H. P., Kunze S. and Steiner H. H. (2002) Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int. J. Cancer 98, 362369.
  • Huttunen H. J. and Rauvala H. (2004) Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J. Intern. Med. 255, 351366.
  • Kato S., Ishihara K., Shinozawa T. et al. (1999) Monoclonal antibody to human midkine reveals increased midkine expression in human brain tumors. J. Neuropathol. Exp. Neurol. 58, 430441.
  • Krueger N. X. and Saito H. (1992) A human transmembrane protein-tyrosine-phosphatase, PTP zeta, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases. Proc. Natl Acad. Sci. USA 89, 74177421.
  • Levy J. B., Canoll P. D., Silvennoinen O. et al. (1993) The cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous system. J. Biol. Chem. 268, 10 57310 581.
  • Lorente G., Nelson A., Mueller S., Kuo J., Urfer R., Nikolich K. and Foehr E. D. (2005) Functional comparison of long and short splice forms of RPTPβ: implications for glioblastoma treatment. Neurooncology 7, 154163.
  • Lu K. V., Jong K. A., Kim G. Y., Singh J., Dia E. Q., Yoshimoto K., Wang M. Y., Cloughesy T. F., Nelson S. F. and Mischel P. S. (2005) Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J. Biol. Chem. 280, 26 95326 964.
  • Maeda N. and Noda M. (1998) Involvement of receptor-like protein tyrosine phosphatase zeta/RPTPbeta and its ligand pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) in neuronal migration. J. Cell Biol. 142, 203216.
  • Meng K., Rodriguez-Pena A., Dimitrov T., Chen W., Yamin M., Noda M. and Deuel T. F. (2000) Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta. Proc. Natl Acad. Sci. USA 97, 26032608.
  • Mentlein R. and Held-Feindt J. (2002) Pleiotrophin, an angiogenic and mitogenic growth factor, is expressed in human gliomas. J. Neurochem. 83, 747753.
  • Mishima K., Asai A., Kadomatsu K., Ino Y., Nomura K., Narita Y., Muramatsu T. and Kirino T. (1997) Increased expression of midkine during the progression of human astrocytomas. Neurosci. Lett. 233, 2932.
  • Muller S., Kunkel P., Lamszus K. et al. (2003) A role for receptor tyrosine phosphatase zeta in glioma cell migration. Oncogene 22, 66616668.
  • Muller S., Lamszus K., Nikolich K. and Westphal M. (2004) Receptor protein tyrosine phosphatase zeta as a therapeutic target for glioblastoma therapy. Expert Opin. Ther. Targets 8, 211220.
  • Nelson W. J. and Nusse R. (2004) Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303, 14831487.
  • Peles E., Schlessinger J. and Grumet M. (1998) Multi-ligand interactions with receptor-like protein tyrosine phosphatase beta: implications for intercellular signaling. Trends Biochem. Sci. 23, 121124.
  • Punnonen E. L., Fages C., Wartiovaara J. and Rauvala H. (1999) Ultrastructural localization of beta-actin and amphoterin mRNA in cultured cells: application of tyramide signal amplification and comparison of detection methods. J. Histochem. Cytochem. 47, 99112.
  • Ruiz C., Huang W., Hegi M. E., Lange K., Hamou M. F., Fluri E., Oakeley E. J., Chiquet-Ehrismann R. and Orend G. (2004) Growth promoting signaling by tenascin-C [corrected]. Cancer Res. 64, 73777385.
  • Stan A. C., Nemati M. N., Pietsch T., Walter G. F. and DietZ. H. (1995) In vivo inhibition of angiogenesis and growth of the human U-87 malignant glial tumor by treatment with an antibody against basic fibroblast growth factor. J. Neurosurg. 82, 10441052.
  • Taguchi A., Blood D. C., Del Toro G. et al. (2000) Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases. Nature 405, 354360.
  • Takei Y., Kadomatsu K., Yuasa K., Sato W. and Muramatsu T. (2005) Morpholino antisense oligomer targeting human midkine: its application for cancer therapy. Int. J. Cancer 114, 490497.
  • Ulbricht U., Brockmann M. A., Aigner A., Eckerich C., Muller S., Fillbrandt R., Westphal M. and Lamszus K. (2003) Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas. J. Neuropathol. Exp. Neurol. 62, 12651275.
  • Zagzag D., Shiff B., Jallo G. I., Greco M. A., Blanco C., Cohen H., Hukin J., Allen J. C. and Friedlander D. R. (2002) Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. Cancer Res. 62, 26602668.
  • Zhang N., Zhong R. and Deuel T. F. (1999) Domain structure of pleiotrophin required for transformation. J. Biol. Chem. 274, 12 95912 962.
  • Zheng X. M., Wang Y. and Pallen C. J. (1992) Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase. Nature 359, 336339.